Key Highlights
- DGX is trading up 0.48% at $238.27 on October 21, with a market capitalization of about $26.30 billion.
- Third-quarter results are due Thursday, October 22, before the open, with a call at 8:30 a.m. ET.
- Second-quarter adjusted EPS was $3.12 on revenue of $3.04 billion.
- The 2026 adjusted EPS guide was raised in July to $11.05 to $11.25.
- Trailing EPS is $9.43, the P/E is 25.27 and the dividend yield is 1.40%.
Is Quest Diagnostics Carrying a Four-Quarter Beat Streak Into Thursday's Earnings?
Quest Diagnostics (NYSE:DGX) is trading up 0.48% at $238.27 on October 21, and no company announcement was identified for the session. The company will report fiscal third-quarter results on Thursday, October 22, before the open, with a call at 8:30 a.m. ET.
What investors may be overlooking is that the streak raises the standard. The company has beaten estimates for EPS and revenue in each of the last four quarters, and in July it lifted its full-year guidance. Another beat would extend the pattern, while a miss would break it, and the market is waiting to see which outcome the guide commentary supports.
What Did the Second-Quarter Results Set Up for Thursday?
In the second quarter, adjusted EPS of $3.12 beat an estimate of $2.82 by about 10.6%, and revenue of $3.04 billion beat $2.97 billion by about 2.4%, both calculated. That marked a fourth straight quarter of beats on both lines.
Management raised full-year adjusted EPS guidance to $11.05 to $11.25 from $10.63 to $10.83, a midpoint increase of about 3.9% (calculated). Revenue guidance rose to $11.95 billion to $12.05 billion from $11.78 billion to $11.90 billion.
Reported trailing EPS is $9.43 on a GAAP basis, up 12.73%, and the P/E is 25.27. Full-year adjusted EPS consensus is about $11.19, so the two measures are not a like-for-like guide. The dividend yield is 1.40%.
What Would a Strong or Weak Quarter Look Like for the Lab Operator?
The metrics that decide the reaction are organic test volume, revenue per requisition, growth in Advanced Diagnostics and margins. A positive signal would be another beat on EPS and revenue, along with a further guide raise that extends the pattern.
A negative signal would be a guide held flat, softer volumes or margin pressure, particularly given the four-quarter record. With the full-year range already lifted once, the fourth-quarter implied by the guide is where commentary may matter as much as the third-quarter print.
News flow into the report has been steady. On October 20 the company announced a collaboration with Waters (NYSE:WAT) on an at-home cervical cancer screening offering planned for 2027. Study data on aldosteronism and minimal residual disease tests also appeared in October.
How Are Research Firms Positioned Ahead of the Report?
The consensus analyst rating is Buy. Barclays set a Buy rating with a $250 target on September 23, Truist is at Hold with $260, UBS at Hold with $245 and Morgan Stanley at Buy with $260. These are data points, not endorsements.
The company provides diagnostic information services, including clinical laboratory testing, so the next question is whether volume and mix can support guidance that has already been raised once this year. Investors will watch the third-quarter figures, any change to the 2026 guide and commentary on volume trends into the fourth quarter.






Please wait processing your request...